FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4284890166> ?p ?o ?g. }

• W4284890166 endingPage "933" @default.
• W4284890166 startingPage "919" @default.
• W4284890166 abstract "Asthma treatment guidelines advocate the use of long-acting beta2-agonists (LABA) in addition to inhaled corticosteroids (ICS) in patients whose asthma is uncontrolled by ICS alone. This is the first study done in Romania, which collected the real-world data on the effects of Foster® (extrafine beclomethasone dipropionate/formoterol fumarate BDP/FF in a pressurized metered-dose inhaler pMDI 100/6 μg formulation) in adult asthmatic population.We aimed to assess the asthma symptoms control, pulmonary function and quality of life parameters in a heterogeneous Romanian asthmatic adult outpatient population, treated with extrafine BDP/FF 100/6 μg pMDI.This was a prospective, multicenter, observational study involving 30 pulmonologists randomly selected from the Romanian healthcare system, which did not declare any competing interests. Recruitment period was Oct 2018 - Feb 2019, while the patients' observational period was 24 weeks. The study included poorly controlled and uncontrolled adult asthma outpatients treated with non-extrafine formulations medication, for which the treatment indication, according to Global Initiative for Asthma (GINA) 2018, was the use of an ICS-LABA combination. The study collected demographic data, smoking habits, comorbidities, data regarding asthma diagnosis, the evolution of asthma symptoms, spirometry, Asthma Control Questionnaire (ACQ-7) scoring test, current and concomitant treatment.Of 302 included patients, 290 completed the study. Pulmonary function parameters assessed during the trial (forced expiratory volume in one second - FEV1 and forced vital capacity - FVC) showed a significant improvement versus baseline (p<0.001). ACQ-7 score decreased significantly from 3.09±0.83 (visit 1) to 1.56±0.89 (visit 2) and to 1.09±0.81 (visit 3) (p<0.001). At the end of the study, 127 (43.79%) patients were well controlled (ACQ-7 score < 0.75).This observational study demonstrates the effectiveness and safety of extrafine fixed combination of BDP/FF (100/6 μg) pMDI in Romanian adult asthma patients uncontrolled with non-extrafine medication in a real-world setting, leading to clinically and statistically improvements in asthma control and pulmonary function." @default.
• W4284890166 created "2022-07-09" @default.
• W4284890166 creator A5017678309 @default.
• W4284890166 creator A5038295979 @default.
• W4284890166 creator A5081051651 @default.
• W4284890166 date "2022-07-01" @default.
• W4284890166 modified "2023-09-25" @default.
• W4284890166 title "Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study)" @default.
• W4284890166 cites W1519188036 @default.
• W4284890166 cites W1962391690 @default.
• W4284890166 cites W1966718625 @default.
• W4284890166 cites W1969489149 @default.
• W4284890166 cites W1985171602 @default.
• W4284890166 cites W2013350088 @default.
• W4284890166 cites W2027673896 @default.
• W4284890166 cites W2028263041 @default.
• W4284890166 cites W2038850183 @default.
• W4284890166 cites W2049725837 @default.
• W4284890166 cites W2052589390 @default.
• W4284890166 cites W2085195759 @default.
• W4284890166 cites W2085294706 @default.
• W4284890166 cites W2087990468 @default.
• W4284890166 cites W2092256487 @default.
• W4284890166 cites W2095989345 @default.
• W4284890166 cites W2110658984 @default.
• W4284890166 cites W2111609315 @default.
• W4284890166 cites W2115852685 @default.
• W4284890166 cites W2156543153 @default.
• W4284890166 cites W2161775889 @default.
• W4284890166 cites W2165209634 @default.
• W4284890166 cites W2168204389 @default.
• W4284890166 cites W2171331726 @default.
• W4284890166 cites W2325639638 @default.
• W4284890166 cites W2463528997 @default.
• W4284890166 cites W2799286435 @default.
• W4284890166 cites W2913920522 @default.
• W4284890166 cites W3207972393 @default.
• W4284890166 doi "https://doi.org/10.2147/jaa.s358798" @default.
• W4284890166 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35836969" @default.
• W4284890166 hasPublicationYear "2022" @default.
• W4284890166 type Work @default.
• W4284890166 citedByCount "0" @default.
• W4284890166 crossrefType "journal-article" @default.
• W4284890166 hasAuthorship W4284890166A5017678309 @default.
• W4284890166 hasAuthorship W4284890166A5038295979 @default.
• W4284890166 hasAuthorship W4284890166A5081051651 @default.
• W4284890166 hasBestOaLocation W42848901661 @default.
• W4284890166 hasConcept C126322002 @default.
• W4284890166 hasConcept C159110408 @default.
• W4284890166 hasConcept C165637977 @default.
• W4284890166 hasConcept C1862650 @default.
• W4284890166 hasConcept C187212893 @default.
• W4284890166 hasConcept C23131810 @default.
• W4284890166 hasConcept C2776042228 @default.
• W4284890166 hasConcept C2776136866 @default.
• W4284890166 hasConcept C2777714996 @default.
• W4284890166 hasConcept C2779871671 @default.
• W4284890166 hasConcept C2779951463 @default.
• W4284890166 hasConcept C2780333948 @default.
• W4284890166 hasConcept C2908647359 @default.
• W4284890166 hasConcept C3018587741 @default.
• W4284890166 hasConcept C55520419 @default.
• W4284890166 hasConcept C71924100 @default.
• W4284890166 hasConcept C75603125 @default.
• W4284890166 hasConcept C99454951 @default.
• W4284890166 hasConceptScore W4284890166C126322002 @default.
• W4284890166 hasConceptScore W4284890166C159110408 @default.
• W4284890166 hasConceptScore W4284890166C165637977 @default.
• W4284890166 hasConceptScore W4284890166C1862650 @default.
• W4284890166 hasConceptScore W4284890166C187212893 @default.
• W4284890166 hasConceptScore W4284890166C23131810 @default.
• W4284890166 hasConceptScore W4284890166C2776042228 @default.
• W4284890166 hasConceptScore W4284890166C2776136866 @default.
• W4284890166 hasConceptScore W4284890166C2777714996 @default.
• W4284890166 hasConceptScore W4284890166C2779871671 @default.
• W4284890166 hasConceptScore W4284890166C2779951463 @default.
• W4284890166 hasConceptScore W4284890166C2780333948 @default.
• W4284890166 hasConceptScore W4284890166C2908647359 @default.
• W4284890166 hasConceptScore W4284890166C3018587741 @default.
• W4284890166 hasConceptScore W4284890166C55520419 @default.
• W4284890166 hasConceptScore W4284890166C71924100 @default.
• W4284890166 hasConceptScore W4284890166C75603125 @default.
• W4284890166 hasConceptScore W4284890166C99454951 @default.
• W4284890166 hasLocation W42848901661 @default.
• W4284890166 hasLocation W42848901662 @default.
• W4284890166 hasLocation W42848901663 @default.
• W4284890166 hasOpenAccess W4284890166 @default.
• W4284890166 hasPrimaryLocation W42848901661 @default.
• W4284890166 hasRelatedWork W153523923 @default.
• W4284890166 hasRelatedWork W2082677861 @default.
• W4284890166 hasRelatedWork W2116970310 @default.
• W4284890166 hasRelatedWork W2375063122 @default.
• W4284890166 hasRelatedWork W2409589510 @default.
• W4284890166 hasRelatedWork W2800725055 @default.
• W4284890166 hasRelatedWork W2936761846 @default.
• W4284890166 hasRelatedWork W4214510678 @default.
• W4284890166 hasRelatedWork W4312304745 @default.
• W4284890166 hasRelatedWork W2182409042 @default.

• next